YKL-40 and the Cellular Metabolic Profile in Parkinson’s Disease
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242216297 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Maria Gevezova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Medical University, 4000 Plovdiv, Bulgaria. Hauptthemen laut MEDLINE: Parkinson Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria.
Abstract (Originalsprache)
Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide. A growing body of evidence suggests that mitochondrial dysfunction and inflammation play a crucial role as a pathogenetic mechanism in PD. The glycoprotein YKL-40 (CHI3L1) is a potential biomarker involved in inflammation and tumor processes. The aim of the present study was to investigate the metabolic profile of PBMCs from PD patients and to search for a possible relationship between cellular bioenergetics and YKL-40. The study included 18 naïve PD patients and an age-matched control group (HC, n = 7). Patients were diagnosed according to the MDS-PD, the UPDRS, and the Hoen–Yahr scales. Mitochondrial activity was measured by a metabolic analyzer on isolated PBMCs from PD patients. Gene (qPCR) and protein (ELISA) expression levels of YKL40 were investigated. New data are reported revealing changes in the mitochondrial activity and YKL-40 levels in PD patients. Bioenergetic parameters showed increased respiratory reserve capacity in PD compared to HC. The protein levels of YKL-40 were threefold higher in PD. We found a correlation between the YKL-40 protein levels and basal respiration and between YKL-40 and ATP production. These observations suggest an interplay between YKL-40 and mitochondrial function in PD. We assume that the YKL-40 gene and protein levels in combination with changes in mitochondrial function might serve as an additional tool to monitor the clinical course of PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Medical University, 4000 Plovdiv, Bulgaria.
- Research Institute at MU-Plovdiv, 4000 Plovdiv, Bulgaria.
- Department of Neurology, Medical University, 4000 Plovdiv, Bulgaria.
- University Hospital "Kaspela", 4000 Plovdiv, Bulgaria.
ORCID-Profile: Victoria Sarafian
Förderung
- European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria
Zitieren
APA
Gevezova, M., Kazakova, M., Trenova, A., & Sarafian, V. (2023). YKL-40 and the Cellular Metabolic Profile in Parkinson’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216297
Vancouver
Gevezova M, Kazakova M, Trenova A, Sarafian V. YKL-40 and the Cellular Metabolic Profile in Parkinson’s Disease. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216297
BibTeX
@article{Gevezova2023,
author = {Gevezova, Maria and Kazakova, Maria and Trenova, Anastasia and Sarafian, Victoria},
title = {YKL-40 and the Cellular Metabolic Profile in Parkinson’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242216297}
}
EUVIMED